Leo Luznik

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. Kanakry C, Bakoyannis G, Perkins S, McCurdy S, Vulic A, Warren E, et al. Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide. Haematologica. 2017;102:932-940 pubmed publisher
    ..These data confirm that plasma-derived proteins previously assessed in other transplantation platforms appear to retain prognostic and predictive utility in patients treated with post-transplantation cyclophosphamide. ..
  2. McCurdy S, Kanakry C, Tsai H, Gojo I, Smith B, Gladstone D, et al. Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2018;: pubmed publisher
    ..001) after HLA-matched BMT with PTCy. The ability of PTCy to limit grades III to IV aGVHD and cGVHD while maintaining grade II aGVHD may contribute to its effectiveness, and further attempts to reduce aGVHD may be detrimental. ..
  3. Kanakry C, O Donnell P, Furlong T, de Lima M, Wei W, Medeot M, et al. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014;32:3497-505 pubmed publisher
  4. Robinson T, O Donnell P, Fuchs E, Luznik L. Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol. 2016;53:90-7 pubmed publisher
  5. McCurdy S, Kasamon Y, Kanakry C, Bolaños Meade J, Tsai H, Showel M, et al. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 2017;102:391-400 pubmed publisher
    ..Although limited by inclusion of dissimilar cohorts, we found that post-transplantation cyclophosphamide-based platforms yield comparable composite endpoints across conditioning intensity, donor type, and HLA match. ..
  6. Luznik L, O Donnell P, Fuchs E. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39:683-93 pubmed publisher
    ..This review discusses the history of HLA-haploidentical SCT, recent clinical results, and immunologic mechanisms of action of high-dose PT/Cy for prevention of graft rejection and GVHD. ..